XM levert geen diensten aan inwoners van de Verenigde Staten.

XM levert geen diensten aan inwoners van de Verenigde Staten.
V
V

Vertex

Nieuws

Reuters - 58 minuten geleden

Vertex: Genomics PLC Announces New Extension And Expansion Of Drug Discovery Collaboration With Co

BRIEF-Vertex: Genomics PLC Announces New Extension And Expansion Of Drug Discovery Collaboration With Co July 16 (Reuters) - Vertex Pharmaceuticals Inc VRTX.O : GENOMICS PLC ANNOUNCES NEW EXTENSION AND EXPANSION OF DRUG DISCOVERY COLLABORATION WITH VERTEX GENOMICS PLC - THREE-YEAR EXTENSION OF COLLABORATION TO USE GENOMICS TO ACCELERATE DRUG DISCOV
V
Reuters - 3 uur geleden

Orum Therapeutics Anoounces Global, Multi-Target License, Option Agreement With Vertex For Use Of Orum's TPD Technology

BRIEF-Orum Therapeutics Anoounces Global, Multi-Target License, Option Agreement With Vertex For Use Of Orum's TPD Technology July 16 (Reuters) - Vertex Pharmaceuticals Inc VRTX.O : ORUM THERAPEUTICS-GLOBAL, MULTI-TARGET LICENSE, OPTION AGREEMENT WITH VERTEX FOR USE OF ORUM'S TPD² TECHNOLOGY TO DEVELOP DEGRADER-ANTIBODY CONJUGATES ORUM THERAPEUTIC
V
Reuters - 21 uur geleden

Vertex sues US over fertility support program for Casgevy gene editing therapy

UPDATE 2-Vertex sues US over fertility support program for Casgevy gene editing therapy Adds OIG response July 15 (Reuters) - Vertex Pharmaceuticals VRTX.O sued the U.S. Department of Health and Human Services on Monday, seeking a court declaration that a fertility support program for patients who are prescribed its gene editing therapy Casgevy does not violate federal anti-kickback laws.
V
Reuters - 21 uur geleden

Vertex sues US over Casgevy gene editing therapy

Vertex sues US over Casgevy gene editing therapy July 15 (Reuters) - Vertex Phamaceuticals VRTX.O sued the U.S. Department of Health and Human Services on Monday, seeking a court declaration that a fertility support program for patients who are prescribed its gene editing therapy Casgevy does not violate federal anti-kickback laws. The lawsuit was filed on the federal court in Washington, D.C.
V
Reuters - 2 weken geleden

Vertex Pharmaceuticals Says Vanza Triple Granted Priority Review With Prescription Drug User Fee Act

BRIEF-Vertex Pharmaceuticals Says Vanza Triple Granted Priority Review With Prescription Drug User Fee Act July 2 (Reuters) - Vertex Pharmaceuticals Inc VRTX.O : VERTEX ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR VANZACAFTOR/TEZACAFTOR/DEUTIVACAFTOR, A NEXT-IN-CLASS TRIPLE COMBINATION TREATMENT FOR CYSTIC FIBROSIS VERTEX PHARMACEUTICALS IN
V
Reuters - 3 weken geleden

U.S. Campbell Soup, Tesla, Walgreens

U.S. RESEARCH ROUNDUP-Campbell Soup, Tesla, Walgreens June 26 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Campbell Soup, Tesla and Walgreens, on Wednesday. HIGHLIGHTS * Campbell Soup Co CPB.N : JP Morgan raises to overweight from neutral * Kratos Defense and Security Solutions KTOS.O : BTIG initiates coverage with Neutral rating * Rocket Lab USA Inc RKLB.O : BTIG initiates coverage with Neutral rating * Tesla Inc
A
A
C
D
G
L
N
P
T
V
W
U
C
A
F
H
Reuters - 1 maand geleden

Vertex Announces Positive Long-Term Data On Casgevy; Safety Profile Consistent With Busulfan Conditioning Andautologous Hematopoietic Stem Cell Transplant

BRIEF-Vertex Announces Positive Long-Term Data On Casgevy; Safety Profile Consistent With Busulfan Conditioning Andautologous Hematopoietic Stem Cell Transplant June 14 (Reuters) - Vertex Pharmaceuticals Inc VRTX.O : VERTEX PRESENTS POSITIVE LONG-TERM DATA ON CASGEVY™ (EXAGAMGLOGENE AUTOTEMCEL) AT THE 2024 ANNUAL EUROPEAN HEMATOLOGY ASSOCIATION (
V
Reuters - 1 maand geleden

New Pharma will crowd out Big Pharma

BREAKINGVIEWS-New Pharma will crowd out Big Pharma The author is a Reuters Breakingviews columnist. The opinions expressed are her own. By Aimee Donnellan LONDON, June 11 (Reuters Breakingviews) - Big Pharma is under threat from tech-driven upstart rivals. The values of large, established players like $159 billion Pfizer PFE.N , $230 billion Novartis NOVN.S and $216 billion Roche ROG.S are converging with newer players like $121 billion Vertex Pharmaceuticals VRTX.O .
A
G
N
P
R
R
S
V
Reuters - 1 maand geleden

U.S. Biomea Fusion, Enphase Energy, Perion Network

U.S. RESEARCH ROUNDUP-Biomea Fusion, Enphase Energy, Perion Network June 11 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several US-listed companies, including Biomea Fusion, Enphase Energy and Perion Network, on Tuesday. HIGHLIGHTS * Biomea Fusion Inc BMEA.O : Truist Securities cuts to hold from buy * Cleveland-Cliffs Inc CLF.N : JP Morgan cuts to neutral from overweight * Enphase Energy Inc ENPH.O : HSBC raises to buy from hold * Perion Network Ltd PER
A
G
H
I
M
M
N
V
W
D
Reuters - 1 maand geleden

Vertex Says Presents New Data At The European Cystic Fibrosis Conference Demonstrating Significant Benefits Of Treatment With Trikafta®

BRIEF-Vertex Says Presents New Data At The European Cystic Fibrosis Conference Demonstrating Significant Benefits Of Treatment With Trikafta® June 7 (Reuters) - Vertex Pharmaceuticals Inc VRTX.O : VERTEX PRESENTS NEW DATA AT THE EUROPEAN CYSTIC FIBROSIS CONFERENCE DEMONSTRATING SIGNIFICANT BENEFITS OF TREATMENT WITH TRIKAFTA® VERTEX PHARMACEUTICA
V
Reuters - 1 maand geleden

Nasdaq top and bottom performing stocks at about 03:45 p.m. EDT

BUZZ - Nasdaq top and bottom performing stocks at about 03:45 p.m. EDT Nasdaq 100 .NDX Top Performers Percent Change Autodesk Inc ADSK.OQ +4.4% NVIDIA Corp NVDA.OQ +4.2% Moderna Inc MRNA.OQ +3.6% Vertex Pharmaceuticals Inc VRTX.OQ +2.5% Dollar Tree Inc DLTR.OQ +2.4% Bottom Performers Percent Change Diamondback Energy Inc FANG.OQ -5.0% Constellation Energy Corp CEG.OQ -4.6% Baker Hughes Co BKR.OQ -4.1% Dexcom Inc DXCM.OQ -3.6% Old Dominion Freight Line Inc ODFL.OQ -3.4% The Nasdaq 100 .NDX lost 6
A
N
V
D
U
D
D
O
Reuters - 1 maand geleden

Nasdaq top and bottom performing stocks at about 12:01 p.m. EDT

BUZZ - Nasdaq top and bottom performing stocks at about 12:01 p.m. EDT Nasdaq 100 .NDX Top Performers Percent Change Autodesk Inc ADSK.OQ +6.0% NVIDIA Corp NVDA.OQ +4% Moderna Inc MRNA.OQ +2.8% Vertex Pharmaceuticals Inc VRTX.OQ +2.8% MongoDB Inc MDB.OQ +2.4% Bottom Performers Percent Change Constellation Energy Corp CEG.OQ -4.8% Diamondback Energy Inc FANG.OQ -4.7% Baker Hughes Co BKR.OQ -3.7% Old Dominion Freight Line Inc ODFL.OQ -2.8% Fastenal Co FAST.OQ -2.5% The Nasdaq 100 .NDX gained 26.35
A
F
N
V
U
D
O
Reuters - 2 maanden geleden

Nasdaq top and bottom performing stocks at about 03:45 p.m. EDT

BUZZ - Nasdaq top and bottom performing stocks at about 03:45 p.m. EDT Nasdaq 100 .NDX Top Performers Percent Change Constellation Energy Corp CEG.OQ +3.6% Datadog Inc DDOG.OQ +3.5% Vertex Pharmaceuticals Inc VRTX.OQ +2.6% Charter Communications Inc CHTR.OQ +2.2% Amgen Inc AMGN.OQ +1.9% Bottom Performers Percent Change Zscaler Inc ZS.OQ -4.0% Electronic Arts Inc EA.OQ -3.6% Trade Desk Inc TTD.OQ -3.6% Atlassian Corp TEAM.OQ -2.9% PayPal Holdings Inc PYPL.OQ -2.8% The Nasdaq 100 .NDX lost 7.12 po
A
C
P
V
E
U
A
T
Reuters - 2 maanden geleden

U.S. Perficient, Target, Vertex Pharmaceuticals

U.S. RESEARCH ROUNDUP- Perficient, Target, Vertex Pharmaceuticals May 7 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Perficient, Target and Vertex Pharmaceuticals, on Tuesday. HIGHLIGHTS * Cerence Inc CRNC.O : Needham cuts to hold from buy * Gap Inc GPS.N : Citigroup raises to buy from neutral * Perficient Inc PRFT.O : Alliance Global Partners cuts to neutral from buy * Target Corp TGT.N : Citigroup raises to buy
A
C
V
M
F
I
S
H
P
Reuters - 2 maanden geleden

Vertex tops Q1 profit estimates on robust demand for cystic fibrosis treatments

UPDATE 1-Vertex tops Q1 profit estimates on robust demand for cystic fibrosis treatments Adds executive comments in paragraphs 5, 9 and 11 By Pratik Jain May 6 (Reuters) - Vertex Pharmaceuticals VRTX.O beat Wall Street estimates for first-quarter profit on Monday, driven by robust uptake for its blockbuster cystic fibrosis treatments. Cystic fibrosis (CF) - an inherited disorder that causes severe damage to the lungs, digestive system and other organs - affects an estimated 105,000 people across
V
Reuters - 2 maanden geleden

Vertex Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary

Vertex Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary Vertex Pharmaceuticals Inc VRTX.OQ reported quarterly adjusted earnings of $4.76​​ per share for the quarter ended in March, higher than the same quarter last year, when the company reported EPS of $3.05. The mean expectation of twenty five analysts for the quarter was for earnings of $4.06 per share.
V
Reuters - 2 maanden geleden

Vertex Pharmaceuticals Reiterated FY 2024 Financial Guidance

BRIEF-Vertex Pharmaceuticals Reiterated FY 2024 Financial Guidance May 6 (Reuters) - Vertex Pharmaceuticals Inc VRTX.O : VERTEX PHARMACEUTICALS - Q1 ADJUSTED EPS $4.76 VERSUS LSEG IBES ESTIMATE $4.06 VERTEX PHARMACEUTICALS - REITERATED FY 2024 FINANCIAL GUIDANCE, INCLUDING PRODUCT REVENUE GUIDANCE OF $10.55 BILLION TO $10.75 BILLION VERTEX PHARMACE
V
Reuters - 2 maanden geleden

Vertex tops Q1 profit estimates on robust demand for cystic fibrosis treatments

Vertex tops Q1 profit estimates on robust demand for cystic fibrosis treatments May 6 (Reuters) - Vertex Pharmaceuticals VRTX.O beat Wall Street estimates for first-quarter profit on Monday, driven by robust uptake for its cystic fibrosis treatments. Cystic fibrosis (CF) - an inherited disorder that causes severe damage to the lungs, digestive system and other organs - affects an estimated 105,000 people across 94 countries, according to data from U.S.-based CF Foundation.
V
Reuters - 2 maanden geleden

Vertex Pharmaceuticals Q1 Net Income USD 1,099.6 Million

BRIEF-Vertex Pharmaceuticals Q1 Net Income USD 1,099.6 Million May 06 (Reuters) - Vertex Pharmaceuticals Q1 pretax profit USD 1,279.1 million vs. IBES estimate USD 1,298 million. Q1 revenue USD 2,690.6 million vs. IBES estimate USD 2,579 million Q1 operating income USD 1,139.5 million outlook FY product revenue USD 10,550-10,750 million
V
Reuters - 2 maanden geleden

Relief (mostly) everywhere

MORNING BID AMERICAS-Relief (mostly) everywhere A look at the day ahead in U.S. and global markets from Dhara Ranasinghe. The relief across world markets as signs of a softening in the U.S. jobs markets strengthens the case for Federal Reserve rate cuts to start later this year remains palpable. Not only did U.S. 10-year Treasury yields end Friday down 17 basis points US10YT=RR , in their biggest weekly drop of the year, but the S&P 500 stock index had its best day in over two months.
A
U
V
M
U
S
I

Voorwaarden

Populaire activa

Disclaimer: De entiteiten van de XM Group bieden diensten en toegang tot ons online handelsplatform op basis van uitsluitend-uitvoering, waardoor een persoon de beschikbare content op of via de website kan bekijken en/of gebruiken, zonder dat dit is bedoeld voor wijziging of uitbreiding. Dergelijk(e) toegang en gebruik vallen onder: (i) de algemene voorwaarden; (ii) risicowaarschuwingen; en de (iii) volledige disclaimer. Dergelijke content wordt daarom alleen aangeboden als algemene informatie. Wees u er daarnaast vooral van bewust dat de inhoud op ons online handelsplatform geen verzoek of aanbieding omvat om transacties op de financiële markten uit te voeren. Het beleggen op welke financiële markt dan ook vormt een aanzienlijk risico voor uw vermogen.

Alle materialen die op ons online handelsplatform worden gepubliceerd zijn bedoeld voor educatieve/informatieve doeleinden en omvatten geen – en moeten niet worden beschouwd als het bevatten van – financieel, vermogensbelastings- of handelsadvies en aanbevelingen, of een overzicht van onze handelsprijzen, of een aanbod of aanvraag van een transactie in financiële instrumenten of ongevraagde financiële promoties voor u.

Alle content van derden, alsmede content die is voorbereid door XM, zoals opinies, nieuws, onderzoeken, analyses, prijzen en andere informatie of koppelingen naar externe websites op deze website worden aangeboden op een 'zoals-ze-zijn'-basis, als algemene marktcommentaren, en vormen geen beleggingsadvies. Voor zover dat content wordt beschouwd als beleggingsonderzoek, moet u zich ervan bewust zijn en accepteren dat de content niet bedoeld was en niet is voorbereid in overeenstemming met de wettelijke vereisten die zijn opgesteld om de onafhankelijkheid van beleggingsonderzoek te bevorderen en als zodanig onder de geldende wetgeving en richtlijnen moet worden beschouwd als marketingcommunicatie. Zorg ervoor dat u onze Mededeling over niet-onafhankelijk beleggingsonderzoek en risicowaarschuwing in verband met de voorgaande informatie doorneemt en begrijpt; die kunt u hier lezen.

Risicowaarschuwing: Uw vermogen loopt risico. Hefboomproducten zijn mogelijk niet voor iedereen geschikt. Lees onze informatie over risico's.